0.00
—
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Scopus Biopharma
Its shares trade under the ticker SCPS. It has been listed since 16 December 2020.
Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of therapeutics targeting diseases with unmet medical needs. The company is headquartered in New York City, New York. The company went IPO on 2020-12-16. The firm is focused on the development of its immuno-oncology programs. The Company’s Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The firm is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. DUET-02 is being developed for systemic delivery for treatment of solid tumors such as prostate or kidney cancers.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Dec 2020
- Employees
- 13
- Website
- scopusbiopharma.com ↗
Leadership
Pay as last reported
- Mr. Joshua LamsteinChairman of the Board, Principal Executive Officer, since 2020$231,080
- Mr. Robert GibsonVice Chairman of the Board, Treasurer, Secretary$200,000
- Dr. Alan HorsagerPresident - Immuno-Oncology and President and Chief Executive Officer of Duet BioTherapeutics
- Dr. Aharon SchwartzExecutive Chairman of Scopus BioPharma Israel Ltd
- Mr. Ira GreenspanDirector$200,000
- Dr. David BattlemanIndependent Director$45,000
- Mr. David BuckelIndependent Director$55,000
- Dr. Raphael HofsteinIndependent Director$41,333
- Mr. David WeildIndependent Director$55,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 21
- Environment
- 22
- Social
- 24
- Governance
- 16
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Scopus Biopharma focuses on immuno-oncology programs targeting unmet medical needs.
- The Duet Platform utilizes bifunctional oligonucleotides to activate antigen-presenting cells.
- DUET-01 targets relapsed B-cell non-Hodgkin lymphoma with specific efficacy.
Weaknesses
- The company employs only 13 full-time staff members currently.
- Scopus Biopharma is headquartered in New York City, US.
- The firm went public on 16 December 2020 via IPO.
Opportunities
- DUET-02 is developed for solid tumors like prostate or kidney cancers.
- The Duet Platform alleviates tumor immunosuppression to jump-start immune responses.
- STAT3 inhibitors linked with TLR9 agonists offer novel therapeutic approaches.
Threats
- Scopus Biopharma operates in the competitive biotechnology sector.
- Relapsed or refractory diseases present complex treatment challenges.
- Developing therapeutics requires significant resources and time investment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.